Pharmafile Logo
Pharmafocus logo
Advanced Search

lymphoma

Showing 15 posts of 30 posts found.

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

April 15, 2024
Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …

News

Viracta Therapeutics completes enrolment for T-cell lymphoma cohort in NAVAL-1 trial

March 1, 2024
Medical Communications Oncology, Viracta Therapeutics, lymphoma

Viracta Therapeutics has announced that it has completed stage 2 enrolment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) …

News

NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL

February 1, 2024
Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma

AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …

News

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023
Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …

News

Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment

December 4, 2023
Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …

News

NMPA approves CStone’s Cejemly for lymphoma treatment

October 31, 2023
Medical Communications CStone, Cejemly, NMPA, Oncology, lymphoma

CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved its anti-PD-L1 antibody Cejemly (sugemalimab) …

News

Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting

June 5, 2023
Research and Development Allogene, LBCL, Oncology, lymphoma, oncology

Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …

News
shutterstock_3

EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma

October 20, 2020
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma

Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …

News
nice_new_london_office_internal_3_web

NICE rejects mycosis fungoides-type cutaneous T-cell lymphoma therapy over data concerns

August 5, 2020
Research and Development, Sales and Marketing Ledaga, NICE, lymphoma

NICE has announced its rejection of Ledaga (chlormethine gel), a topical therapy for the treatment of mycosis fungoides-type cutaneous T-cell …

News
pd36-1-ksc-20170808-ph_csh01_0023

MSD’s Phase 3 study of lymphoma treatment meets primary endpoints

March 3, 2020
Manufacturing and Production B-cell lymphoma, classical Hodgkin Lymphoma, lymphoma

MSD announced that its Phase 3 study of Keytruda (pembrolizumab) for the treatment of adults with relapsed or refractory classical …

News
roche__tree

EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma

January 21, 2020
Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma

The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.

News
china_block_001_takeda_0

Takeda commits to advancing treatments for rare bleeding disorders and cancer

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology

Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …

News

Roche scores FDA approval for Polivy combo in diffuse large B-cell lymphoma

June 11, 2019
Manufacturing and Production, Sales and Marketing Polivy, Roche, lymphoma, pharma

Roche is celebrating the decision taken by the FDA to approve its anti-CD79b antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) in combination …

News
celgene_building

FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma

May 29, 2019
Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma

Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …

News
takeda_usa_pharmaceuticals_u

NICE recommend Takeda’s lymphoma treatment Adcetris

March 25, 2019
Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024